---
figid: PMC5110029__JEM_20161596_Fig1
figlink: /pmc/articles/PMC5110029/figure/fig1/
number: F1
caption: 'Type I interferon signaling and type I interferonopathies as currently assigned.
  Diseases considered as monogenic interferonopathies are represented by blue boxes.
  This schema alludes to at least seven possible cellular mechanisms resulting in
  sustained activation of interferon signaling caused by the following: (1) loss-of-function
  mutations leading to increased cytosolic DNA (TREX1 [] and SAMHD1 [; ]) or RNA/DNA
  hybrid (RNASEH2A, RNASEH2B and RNASEH2C, POLA1) sensing (; ; ); (2) loss-of-function
  mutations leading to a defect in RNA editing and abnormal sensing of self–nucleic
  acid RNA species in the cytosol (ADAR1 [; ]); (3) gain-of-function mutations leading
  to constitutive activation of cytosolic interferon signaling pathways/increased
  sensitivity to cytosolic nucleic acid ligands (MDA5 [], RIG-I [], and STING []);
  (4) loss-of-function mutations leading to aberrant RNA signaling via MAVS caused
  by a disturbance of the unfolded protein response (SKIV2L []); (5) loss-of-function
  mutations in molecules responsible for limiting interferon receptor (IFNAR1/2) signaling
  leading to uncontrolled ISG production (USP18 [] and ISG15 []); (6) proteasomal
  dysfunction leading to increased interferon signaling through an unknown mechanism
  (PSMA3, PSMB4, and PSMB8 []; we do not include the so-far single-published mutations
  in PSMB9 and POMP); and (7) loss-of-function mutations in TRAP/ACP5 (; ) and C1q
  (; ) where we consider the mechanisms leading to type I interferon signaling are
  yet to be fully clarified (we do not include mutations in other molecules of the
  complement pathway as a clear demonstration of enhanced interferon signaling has
  not been established).'
pmcid: PMC5110029
papertitle: 'Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies,
  a conceptual overview.'
reftext: Mathieu P. Rodero, et al. J Exp Med. 2016 Nov 14;213(12):2527-2538.
pmc_ranked_result_index: '50874'
pathway_score: 0.9506725
filename: JEM_20161596_Fig1.jpg
figtitle: Type I interferon signaling and type I interferonopathies as currently assigned
year: '2016'
organisms:
- Homo sapiens
ndex: 43646cc4-def5-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5110029__JEM_20161596_Fig1.html
  '@type': Dataset
  description: 'Type I interferon signaling and type I interferonopathies as currently
    assigned. Diseases considered as monogenic interferonopathies are represented
    by blue boxes. This schema alludes to at least seven possible cellular mechanisms
    resulting in sustained activation of interferon signaling caused by the following:
    (1) loss-of-function mutations leading to increased cytosolic DNA (TREX1 [] and
    SAMHD1 [; ]) or RNA/DNA hybrid (RNASEH2A, RNASEH2B and RNASEH2C, POLA1) sensing
    (; ; ); (2) loss-of-function mutations leading to a defect in RNA editing and
    abnormal sensing of self–nucleic acid RNA species in the cytosol (ADAR1 [; ]);
    (3) gain-of-function mutations leading to constitutive activation of cytosolic
    interferon signaling pathways/increased sensitivity to cytosolic nucleic acid
    ligands (MDA5 [], RIG-I [], and STING []); (4) loss-of-function mutations leading
    to aberrant RNA signaling via MAVS caused by a disturbance of the unfolded protein
    response (SKIV2L []); (5) loss-of-function mutations in molecules responsible
    for limiting interferon receptor (IFNAR1/2) signaling leading to uncontrolled
    ISG production (USP18 [] and ISG15 []); (6) proteasomal dysfunction leading to
    increased interferon signaling through an unknown mechanism (PSMA3, PSMB4, and
    PSMB8 []; we do not include the so-far single-published mutations in PSMB9 and
    POMP); and (7) loss-of-function mutations in TRAP/ACP5 (; ) and C1q (; ) where
    we consider the mechanisms leading to type I interferon signaling are yet to be
    fully clarified (we do not include mutations in other molecules of the complement
    pathway as a clear demonstration of enhanced interferon signaling has not been
    established).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADAR
  - RNASEH2A
  - RNASEH2B
  - IFNA8
  - IFNA10
  - C1QB
  - DDX58
  - PSMB8
  - USP18
  - PSMA3
  - PSMB4
  - IFNAR1
  - RNASEH2C
  - C1QA
  - CGAS
  - IFNA7
  - IFIH1
  - POLA1
  - ACP5
  - TREX1
  - TYK2
  - IFNA16
  - IFNA21
  - IFNA17
  - IFNA1
  - IFNAR2
  - IFNA5
  - IFNA6
  - MAVS
  - IRF3
  - IRF9
  - ISG15
  - IFNA13
  - IFNA14
  - IFNA2
  - IFNA4
  - STAT1
  - JAK1
  - SAMHD1
  - SKIV2L
  - TMEM173
  - STAT2
  - triphosphates
  - Aicardi-Goutieres syndrome
genes:
- word: ADAR1
  symbol: ADAR1
  source: hgnc_alias_symbol
  hgnc_symbol: ADAR
  entrez: '103'
- word: RNASEH2A
  symbol: RNASEH2A
  source: hgnc_symbol
  hgnc_symbol: RNASEH2A
  entrez: '10535'
- word: RNASEH2B
  symbol: RNASEH2B
  source: hgnc_symbol
  hgnc_symbol: RNASEH2B
  entrez: '79621'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA8
  entrez: '3445'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA10
  entrez: '3446'
- word: C1q
  symbol: C1q
  source: bioentities_symbol
  hgnc_symbol: C1QB
  entrez: '713'
- word: RIG-I
  symbol: RIG-I
  source: hgnc_alias_symbol
  hgnc_symbol: DDX58
  entrez: '23586'
- word: PSMB8
  symbol: PSMB8
  source: hgnc_symbol
  hgnc_symbol: PSMB8
  entrez: '5696'
- word: USP18
  symbol: USP18
  source: hgnc_symbol
  hgnc_symbol: USP18
  entrez: '11274'
- word: PSMA3
  symbol: PSMA3
  source: hgnc_symbol
  hgnc_symbol: PSMA3
  entrez: '5684'
- word: PSMB4
  symbol: PSMB4
  source: hgnc_symbol
  hgnc_symbol: PSMB4
  entrez: '5692'
- word: IFNAR1
  symbol: IFNAR1
  source: hgnc_symbol
  hgnc_symbol: IFNAR1
  entrez: '3454'
- word: RNASEH2C
  symbol: RNASEH2C
  source: hgnc_symbol
  hgnc_symbol: RNASEH2C
  entrez: '84153'
- word: C1q
  symbol: C1q
  source: bioentities_symbol
  hgnc_symbol: C1QA
  entrez: '712'
- word: CGAS
  symbol: CGAS
  source: hgnc_symbol
  hgnc_symbol: CGAS
  entrez: '115004'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA7
  entrez: '3444'
- word: MDA5
  symbol: MDA-5
  source: hgnc_alias_symbol
  hgnc_symbol: IFIH1
  entrez: '64135'
- word: POLA1
  symbol: POLA1
  source: hgnc_symbol
  hgnc_symbol: POLA1
  entrez: '5422'
- word: ACP5
  symbol: ACP5
  source: hgnc_symbol
  hgnc_symbol: ACP5
  entrez: '54'
- word: TREX1
  symbol: TREX1
  source: hgnc_symbol
  hgnc_symbol: TREX1
  entrez: '11277'
- word: TYK2
  symbol: TYK2
  source: hgnc_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA16
  entrez: '3449'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA21
  entrez: '3452'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA17
  entrez: '3451'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IFNAR2(
  symbol: IFNAR2
  source: hgnc_symbol
  hgnc_symbol: IFNAR2
  entrez: '3455'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA5
  entrez: '3442'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA6
  entrez: '3443'
- word: MAVS+
  symbol: MAVS
  source: hgnc_symbol
  hgnc_symbol: MAVS
  entrez: '57506'
- word: IRF3
  symbol: IRF3
  source: hgnc_symbol
  hgnc_symbol: IRF3
  entrez: '3661'
- word: IRF9
  symbol: IRF9
  source: hgnc_symbol
  hgnc_symbol: IRF9
  entrez: '10379'
- word: ISG15
  symbol: ISG15
  source: hgnc_symbol
  hgnc_symbol: ISG15
  entrez: '9636'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA13
  entrez: '3447'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA14
  entrez: '3448'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA2
  entrez: '3440'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA4
  entrez: '3441'
- word: STAT1
  symbol: STAT1
  source: hgnc_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: JAK1
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: SAMHD1
  symbol: SAMHD1
  source: hgnc_symbol
  hgnc_symbol: SAMHD1
  entrez: '25939'
- word: SKIV2L
  symbol: SKIV2L
  source: hgnc_symbol
  hgnc_symbol: SKIV2L
  entrez: '6499'
- word: STING
  symbol: STING
  source: hgnc_alias_symbol
  hgnc_symbol: TMEM173
  entrez: '340061'
- word: STAT2
  symbol: STAT2
  source: hgnc_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
chemicals:
- word: triphosphates
  source: MESH
  identifier: C005692
diseases:
- word: Aicardi-Goutieres syndrome
  source: ''
  identifier: ''
figid_alias: PMC5110029__F1
redirect_from: /figures/PMC5110029__F1
figtype: Figure
---
